Enhancing the effectiveness of both cell‐ and antibody‐based therapies against nsGSL‐expressing tumors could be achieved by specific inhibitors of GSL synthesis such as Eliglustat or Miglustat (UGCG inhibitors) which are currently safely applied to patients with lysosomal storage disorders [11]. This evidence concerns the gene UGCG and lysosomal storage disease.